Alzamend Neuro (NASDAQ:ALZN) Director Milton Ault III Sells 101,394 Shares

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 101,394 shares of the firm’s stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $2.44, for a total transaction of $247,401.36. Following the sale, the director owned 28,657 shares in the company, valued at approximately $69,923.08. This trade represents a 77.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Alzamend Neuro Stock Performance

Shares of NASDAQ ALZN opened at $2.18 on Friday. Alzamend Neuro, Inc. has a 1 year low of $2.06 and a 1 year high of $17.10. The firm’s 50 day moving average price is $2.40 and its 200 day moving average price is $3.89.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC bought a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro at the end of the most recent quarter. 49.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ALZN. Ascendiant Capital Markets cut their price target on shares of Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Alzamend Neuro in a research note on Saturday, September 27th. Finally, Wall Street Zen downgraded shares of Alzamend Neuro from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $42.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.